Focused On-demand Library for Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P35913

UPID:

PDE6B_HUMAN

Alternative names:

Alternative UPACC:

P35913; B7Z9T9; E7ETT3; Q53XN5; Q9BWH5; Q9UD49

Background:

The Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta plays a pivotal role in visual signal transduction. It is essential for the hydrolysis of cGMP, a critical step in the phototransduction pathway. This enzyme's activity is crucial for converting light signals into electrical signals in the retina, facilitating vision. Its involvement in retinal circadian rhythm and visual signal amplification underscores its significance in ocular physiology.

Therapeutic significance:

Given its crucial role in vision, mutations affecting this protein are linked to Retinitis pigmentosa 40 and congenital stationary night blindness. These conditions underscore the protein's therapeutic significance, as understanding its function and the impact of its genetic variants could lead to targeted treatments for these debilitating visual disorders.